Lung cancer screening for never-smokers is a more complicated question than it may first appear. Lung cancer is often treated as a smoker’s disease. Smoking is unquestionably its leading cause, but the label is incomplete. In the United States, an estimated 10% to 20% of lung cancers occur in people who have never smoked—generally defined as having smoked fewer than 100 cigarettes during their lifetime.

That raises an understandable question: if low-dose CT screening can find lung cancer earlier in people with a substantial smoking history, should people who have never smoked be screened too?

For most never-smokers, the answer today is no. Major U.S. guidelines do not recommend routine lung cancer screening for this group. The reason is not that never-smokers are immune to lung cancer. It is that screening is beneficial only when the probability of finding a dangerous cancer is high enough to outweigh false alarms, radiation exposure, invasive procedures, and treatment of cancers that might never have caused harm.

Emerging research particularly from East Asia—is challenging us to identify the smaller subset of never-smokers who may face sufficiently elevated risk. But detecting many early-stage cancers is not the same as proving that screening saves lives. Understanding that distinction is essential.

7 critical facts at a glance

1. Lung cancer can occur in people who have never smoked.
2. Low-dose CT screening reduces lung-cancer mortality in selected people with substantial smoking histories.
3. Comparable mortality evidence does not yet exist for never-smokers.
4. Major U.S. guidelines do not recommend routine screening for average-risk never-smokers.
5. Family history, radon, occupational exposures, and prior chest radiation can raise risk.
6. False positives and overdiagnosis become more important when screening lower-risk populations.
7. Symptoms require diagnostic evaluation regardless of smoking history or screening eligibility.

What lung cancer screening actually means

Screening is the use of a test in someone who has no symptoms of the disease. For lung cancer, the recommended screening test is a low-dose computed tomography scan, usually called LDCT.

LDCT creates detailed images of the lungs using substantially less radiation than a conventional diagnostic chest CT. It can identify small nodules that would be invisible on a standard chest X-ray. When screening is limited to people at sufficiently high risk and abnormal findings are managed carefully, this earlier detection can reduce lung-cancer mortality.

The strongest evidence comes from randomized trials involving current and former smokers. In the National Lung Screening Trial, LDCT reduced lung-cancer mortality compared with chest radiography. The European NELSON trial also demonstrated a meaningful reduction compared with no screening. A meta-analysis of randomized studies found an approximately 16% relative reduction in lung-cancer mortality, although it did not demonstrate a statistically significant reduction in overall mortality.

These trials established that LDCT can save lives in a selected high-risk population. They did not establish the same benefit for people who have never smoked, because never-smokers were generally excluded or poorly represented.

Who currently qualifies for lung cancer screening?

The U.S. Preventive Services Task Force recommends annual LDCT screening for adults who:

• Are 50 to 80 years old
• Have accumulated at least 20 pack-years of smoking
• Currently smoke or quit within the past 15 years
• Are healthy enough and willing to undergo evaluation and potentially curative treatment if cancer is found

A pack-year is the equivalent of smoking one pack per day for one year. Someone who smoked one pack daily for 20 years, or two packs daily for 10 years, has a 20-pack-year history.

The American Cancer Society also recommends annual LDCT for adults ages 50 to 80 with at least a 20-pack-year history, but it no longer uses the number of years since quitting as an eligibility cutoff.

Neither organization recommends routine lung cancer screening for never-smokers solely because a person is older, has been exposed to secondhand smoke, or has a family history of lung cancer. The Centers for Disease Control and Prevention specifically advises that the potential harms of screening outweigh the expected benefit for the average person who has never smoked.

These recommendations apply to screening—not to the evaluation of symptoms. A persistent or worsening cough, coughing up blood, unexplained weight loss, chest pain, shortness of breath, or recurrent pneumonia warrants medical attention regardless of smoking history. That is diagnostic evaluation, not screening.

Why lung cancer screening for never-smokers is not routinely recommended

It is tempting to assume that finding cancer earlier must always improve outcomes. Screening science is more complicated.

When a disease is relatively uncommon in the population being tested, even a good test will produce many findings that are not dangerous cancer. LDCT commonly detects small lung nodules, scars, areas of inflammation, and incidental abnormalities in nearby organs. Many of these findings require repeat imaging, and some lead to PET scans, biopsies, bronchoscopy, or surgery.

The major potential harms include:

False-positive results

A scan may appear suspicious even though cancer is not present. Modern systems such as Lung-RADS have reduced false-positive rates by standardizing how nodules are classified and followed, but false alarms remain part of screening. They can cause anxiety, additional radiation exposure, cost, and occasionally invasive procedures with complications.

Overdiagnosis

Overdiagnosis occurs when screening finds a genuine cancer that would never have grown enough to cause symptoms or shorten the person’s life. This is not the same as a false positive: the cells are cancerous, but treating them offers no benefit.

Overdiagnosis is particularly relevant to certain very slow-growing lung adenocarcinomas. Because physicians cannot always know in advance which lesion will remain indolent, a diagnosis may lead to lung surgery or other treatment that the patient never needed.

Radiation exposure

The dose from an individual LDCT scan is low, but screening is repeated annually and an abnormal result may lead to additional scans. The radiation-related cancer risk is small, yet it matters when millions of low-risk people are screened over many years.

Incidental findings

CT images may reveal thyroid nodules, coronary calcification, adrenal lesions, or other unrelated abnormalities. Some findings are useful. Others trigger a cascade of tests without improving health.

The lower a person’s underlying lung-cancer risk, the more these harms weigh against the chance of benefit. That is why a test that is worthwhile for someone with decades of heavy smoking may be a poor trade-off for an average-risk never-smoker.

What the evidence on lung cancer screening for never-smokers shows

The most influential recent evidence comes from the Taiwan Lung Cancer Screening in Never-Smoker Trial, known as TALENT. This prospective study enrolled 12,011 adults ages 55 to 75 who had never smoked or had minimal remote exposure and also had at least one additional risk factor, such as a family history of lung cancer, secondhand smoke exposure, chronic lung disease, or substantial cooking-fume exposure.

LDCT detected lung cancer in 318 participants, or 2.6%. Nearly all were adenocarcinomas, and 77.4% were stage I. Invasive lung cancer was more common among participants with a family history, particularly as age and the number of affected first-degree relatives increased.

These results are important. They show that selecting never-smokers by additional risk factors can produce a higher detection rate than screening an unselected population. They also demonstrate that LDCT can shift diagnosis toward earlier stages.

But TALENT was not a randomized mortality trial. It did not compare screening with no screening to determine whether LDCT reduced lung-cancer deaths. The study’s investigators also acknowledged the possibility of overdiagnosis, particularly for adenocarcinoma in situ.

This is the central uncertainty. Screening can increase the number of cancers found and dramatically improve the apparent five-year survival rate without necessarily preventing deaths. Diagnosing an indolent cancer years earlier makes measured survival after diagnosis look longer even if the date of death does not change—a statistical distortion called lead-time bias. Finding cancers that would never have surfaced creates an additional distortion known as length-time bias.

An International Association for the Study of Lung Cancer report reached a cautious conclusion: screening never-smokers may eventually prove useful, but the evidence does not currently support widespread implementation. More recent studies from East Asia reinforce the need for risk-stratified trials while warning against indiscriminate screening and overtreatment.

This same distinction between a plausible mechanism and a demonstrated health outcome appears throughout preventive medicine. For another evidence-focused example, read The Protein-Cancer Hypothesis.

Which never-smokers may have higher risk?

“Never-smoker” describes smoking history, not total lung-cancer risk. Important risk factors outside active smoking include:

• Radon: A colorless, odorless radioactive gas that can accumulate inside homes. It is an established cause of lung cancer in people who have never smoked.
• Secondhand smoke: Long-term exposure raises lung-cancer risk, although the absolute risk remains much lower than that associated with active smoking.
• Occupational carcinogens: Asbestos, arsenic, diesel exhaust, chromium, nickel, beryllium, cadmium, and silica are among the recognized workplace hazards.
• Air pollution: Long-term exposure to fine particulate matter is associated with lung cancer.
• Prior therapeutic radiation: Radiation to the chest for a previous cancer can increase future lung-cancer risk.
• Chronic lung disease: Pulmonary fibrosis, chronic obstructive pulmonary disease, and certain prior infections may be associated with higher risk.
• Personal or family history: Having had lung cancer or having affected first-degree relatives may indicate greater susceptibility. In TALENT, family history was the clearest risk marker among the factors examined.
• Age and ancestry: Risk rises with age, and lung cancer in never-smokers is proportionally more common in women and in parts of East Asia. Population-specific biology and environmental exposures may affect the screening equation.

No single item on this list automatically establishes that annual LDCT will provide a net benefit. Current risk models for never-smokers are not yet validated well enough for broad clinical adoption, and the evidence may not transfer cleanly from East Asian cohorts to people living in the United States.

A reasonable approach for someone who has never smoked

For an asymptomatic person with no major additional risk factors, scheduling annual CT scans independently is unlikely to be a good preventive strategy. A better approach is to reduce avoidable exposure and identify circumstances that deserve individualized evaluation.

1. Test your home for radon

Radon cannot be seen or smelled. Testing is the only way to know whether it has accumulated indoors. If levels are elevated, established mitigation techniques can reduce exposure. This is one of the most actionable lung-cancer prevention measures available to never-smokers.

2. Review occupational and environmental exposure

People who have worked around asbestos, silica, diesel exhaust, uranium, arsenic, or certain industrial metals should discuss the intensity and duration of exposure with a clinician familiar with occupational medicine. Workplace surveillance protocols may differ from general-population screening guidelines.

3. Build an accurate family history

Record which relatives developed lung cancer, their relationship to you, age at diagnosis, smoking history if known, and the number of affected relatives. One relative who smoked heavily carries a different implication from several never-smoking first-degree relatives diagnosed at younger ages.

4. Do not dismiss symptoms because you never smoked

Never-smokers can develop lung cancer, and symptoms deserve appropriate investigation. A screening guideline should never be used to deny diagnostic testing when symptoms or another clinical finding raises concern.

5. Discuss unusual risk with a specialist

A pulmonologist, thoracic specialist, occupational-medicine physician, or cancer-risk clinic may be appropriate for someone with multiple first-degree relatives, substantial carcinogen exposure, prior chest radiation, pulmonary fibrosis, or a previous lung cancer. The discussion should include not only whether to scan, but also what will happen if a small nodule is found.

6. Consider a clinical trial

For a high-risk never-smoker who wants screening, participation in a well-designed study may offer careful follow-up while contributing to the evidence needed to improve future guidelines.

Questions to ask before choosing an LDCT scan

If screening is being considered outside standard eligibility criteria, useful questions include:

• What is my estimated absolute risk—not merely my relative risk?
• Is the risk model being used validated for never-smokers like me?
• Is the imaging center experienced with LDCT screening and Lung-RADS?
• What follow-up would be recommended for a small nodule?
• How will slow-growing ground-glass lesions be managed to minimize overtreatment?
• Am I healthy and willing enough to undergo biopsy, surgery, or radiation if necessary?
• Would surveillance through a specialist or enrollment in a clinical trial be more appropriate?

The bottom line

Lung cancer among people who have never smoked is not rare enough to ignore. It accounts for a meaningful share of diagnoses, and risk can rise with age, radon exposure, occupational hazards, prior chest radiation, chronic lung disease, and family history.

Still, routine lung cancer screening for never-smokers is not supported by current evidence. We know that screening can find many early-stage cancers in selected populations. We do not yet know whether broad screening of never-smokers reduces mortality enough to outweigh false positives, overdiagnosis, radiation, invasive procedures, and cost.

For now, the most defensible strategy is targeted and individualized: follow established screening criteria for people with a qualifying smoking history, reduce preventable exposures such as radon and secondhand smoke, evaluate symptoms promptly, and discuss exceptional risk with an experienced clinician. The goal is not to scan the greatest number of people. It is to identify those for whom screening is most likely to do more good than harm.

This article is for general educational purposes and does not replace individualized medical advice, diagnosis, or treatment.

For more evidence-based discussions of prevention, longevity, and health risk, visit the Shahab Mokhtare blog.

References

1. Centers for Disease Control and Prevention. Lung Cancer Among People Who Never Smoked.
2. U.S. Preventive Services Task Force. Lung Cancer: Screening Recommendation.
3. Wolf AMD, et al. Screening for lung cancer: 2023 guideline update from the American Cancer Society. CA: A Cancer Journal for Clinicians. 2024.
4. Jonas DE, et al. Screening for Lung Cancer With Low-Dose Computed Tomography: Updated Evidence Report for the USPSTF. JAMA. 2021.
5. Chang GC, et al. Low-dose CT screening among never-smokers with or without a family history of lung cancer in Taiwan. The Lancet Respiratory Medicine. 2024.
6. Kerpel-Fronius A, et al. Screening for Lung Cancer in Individuals Who Never Smoked. Journal of Thoracic Oncology. 2022.
7. National Cancer Institute. Lung Cancer Prevention—Health Professional Version.